title: Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA.
abstract: BACKGROUND
  Prostate cancer is a very common disease in more-developed countries, but its cause is largely unknown. It is an androgen-dependent cancer, and androgens have been proposed as having a substantial role in predisposition to the disease. Thus, variations in androgen metabolism genes may affect risk of this disease.
  
  
  METHODS
  We screened 216 African-American and 172 Hispanic men with prostate cancer, and 261 African-American and 200 Hispanic healthy men (controls), from a large prospective cohort study (the Hawaii-Los Angeles Multiethnic Cohort Study) for a mis-sense substitution in the human prostatic (or type II) steroid 5alpha-reductase (SRD5A2) gene, the product of which controls metabolic activation of testosterone to dihydrotestosterone. This mis-sense substitution results in an alanine residue at codon 49 being replaced with threonine (A49T). We also reconstructed this mutation in the SRD5A2 cDNA, and overexpressed the enzyme in mammalian tissue culture cells.
  
  
  RESULTS
  The A49T aminoacid substitution in the SRD5A2 gene increased the risk of clinically significant disease 7.2-fold in African-American men (95% CI=2.17-27.91; p=0.001) and 3.6-fold in Hispanic men (1.09-12.27; p=0.04). The mutant enzyme had a higher in-vitro Vmax than the normal enzyme (9.9 vs 1.9 nmol min(-1) mg(-1)).
  
  
  CONCLUSIONS
  The A49T variant of the SRD5A2 gene may be a significant contributor to the incidence of prostate cancer in African-American and Hispanic men in Los Angeles. We estimate that the population attributable risk due to this aminoacid substitution for clinically significant disease is about 8% in both populations. Increased conversion of testosterone to dihydrotestosterone catalysed by this variant steroid 5alpha-reductase enzyme may be the cause of the increased risk.
authors.affiliation: Department of Biochemistry and Molecular Biology and Institute for Genetic Medicine, University of Southern California School of Medicine, 90033, USA.
authors.forename: N M
authors.initials: NM
authors.lastname: Makridakis
authors.forename: R K
authors.initials: RK
authors.lastname: Ross
authors.forename: M C
authors.initials: MC
authors.lastname: Pike
authors.forename: L E
authors.initials: LE
authors.lastname: Crocitto
authors.forename: L N
authors.initials: LN
authors.lastname: Kolonel
authors.forename: C L
authors.initials: CL
authors.lastname: Pearce
authors.forename: B E
authors.initials: BE
authors.lastname: Henderson
authors.forename: J K
authors.initials: JK
authors.lastname: Reichardt
mesh_terms: D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000235:genetics*; D001741:Black or African American / Q000706:statistics & numerical data; D000368:Aged; D000728:Androgens / Q000378:metabolism; D016022:Case-Control Studies; D020022:Genetic Predisposition to Disease / Q000235:genetics; D014644:Genetic Variation; D006630:Hispanic or Latino / Q000706:statistics & numerical data; D006801:Humans; D015994:Incidence; D015141:Los Angeles / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D011110:Polymorphism, Genetic; D011471:Prostatic Neoplasms / Q000208:ethnology* / Q000235:genetics*; D012307:Risk Factors
chemical_list: D000728:Androgens; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase